Invivyd Sets Price for $50 Million Public Offering of Common Stock and Pre-Funded Warrants

Public Offering Announcement: Invivyd, Inc. has priced a public offering of 74,811,404 shares of common stock at $0.52 per share, along with pre-funded warrants for an additional 21,342,442 shares at $0.5199 each, aiming to raise approximately $50 million.

Use of Proceeds: The funds will be utilized for trial protocol development, advancing the VYD2311 clinical program, research on respiratory syncytial virus (RSV) and measles, and efforts related to monoclonal antibody therapy for Long COVID and COVID-19 Post-Vaccination Syndrome.

Underwriter Details: Cantor is serving as the sole book-running manager for this offering, which is expected to close around August 22, 2025, pending customary closing conditions.

Forward-Looking Statements: The announcement includes forward-looking statements regarding the offering's proceeds and timing, highlighting potential uncertainties that may affect actual results compared to expectations.